KLK3 and prostate carcinoma: Some authors suggested that PSA is released into the bloodstream by tumor cells after lysis after the treatment transactivates mutant androgen receptors through its estramustine component and premedication with dexamethasone, or by the accelerated differentiation of prostate cancer stem precursors [54].